|
- Brand：Knowlux
- Model：Bottle/Aluminum foil bag/Drum/Customized to your needs
- Purity：99%
- Cas：1415456-99-3
- Createtime： 2026-11-11
- Updatetime： 2026-11-03
| useage | medical intermediate，Pharmaceutical Intermediates |
| deliveryInfo | |
| appearance | White Powder |
| aliasen | |
| supplyCapacity | 10MT/Month |
| harbor | Hong Kong, Shanghai, Shenzhen |
| minorder | 1G |
| Molecular Formula: | C194H312N54O59S2 |
| Sample Available | Yes |
Bremelanotide (PT-141) — Product Details
CAS No.: 189691-06-3
Document Version: November 2026 Verified Edition
Product Classification: Research-Grade Melanocortin Receptor Agonist / Synthetic Peptide
1. Product Identification
| Parameter | Specification |
|---|---|
| Product Name | Bremelanotide |
| Synonyms | PT-141; PT-141 Free Base |
| CAS Registry Number | 189691-06-3 |
| Molecular Formula | C50H68N14O10 |
| Molecular Weight | 1025.18 g/mol |
| Exact Mass | 1024.5243 |
| Appearance | White to off-white lyophilized powder or solid |
| Peptide Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Storage (Lyophilized) | -20°C to -80°C, sealed, desiccated, protected from light |
| Storage (Reconstituted) | Aliquot and store at -20°C; avoid repeated freeze-thaw cycles |
2. Physicochemical Properties
| Property | Value |
|---|---|
| Density | 1.4 ± 0.1 g/cm3 |
| Refractive Index | 1.679 |
| LogP | -1.21 |
| Topological Polar Surface Area (tPSA) | 376.47 A2 |
| Hydrogen Bond Donors | 13 |
| Hydrogen Bond Acceptors | 12 |
| Rotatable Bonds | 17 |
| Heavy Atom Count | 74 |
| Defined Stereocenters | 7 |
3. Quality Specifications & Analytical Verification
This product is supplied strictly as a Research-Use-Only (RUO) reagent. The following parameters constitute the minimum analytical release criteria. A nominal HPLC purity value alone is insufficient as evidence of suitability; peptide content corrected for water and counter-ion, route-derived impurity profile, and residual solvents are equally critical.
| Test Item | Specification / Verification Requirement |
|---|---|
| Chromatographic Purity (HPLC) | >= 98.0% (method and detection wavelength must be stated) |
| Peptide Content (Net) | Calculated on anhydrous, counter-ion-free basis |
| Identity Confirmation | Mass Spectrometry (MW = 1025.18 +/- 0.5 Da) and Amino Acid Analysis |
| Counter-Ion Stoichiometry | Trifluoroacetate (TFA) or Acetate content quantified |
| Residual Solvents | Compliant with ICH Q3C |
| Elemental Impurities | Compliant with ICH Q3D (where applicable) |
| Impurity Profile | Deletion peptides and lactam-opened impurities identified |
| Water Content (Karl Fischer) | Controlled low moisture for lyophilized powder |
| Endotoxin (if applicable) | Specified for parenteral research applications |
4. Pharmacological Background (Research Reference Only)
Receptor Target: Melanocortin receptors, with primary activity at MC4R and MC3R. Bremelanotide is a cyclic heptapeptide lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH).
Approved Therapeutic Indication (Reference): In the United States, bremelanotide is approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This product is sold as a research reagent and is not intended for direct human therapeutic use or compounding.
Regulatory Status Distinction: The same CAS number may apply to materials governed by entirely different quality systems and legal obligations:
| Tier | Quality System | Permitted Use |
|---|---|---|
| Pharmaceutical-grade API | cGMP / ICH Q7 | Commercial manufacturing (licensed) |
| Research-grade (this product) | ISO 9001 / Manufacturer specification | Laboratory in vitro / animal studies |
| Intermediate-grade | Manufacturer specification | Further synthesis or research |
5. Safety & Handling Summary
| Parameter | Information |
|---|---|
| GHS Classification | Not classified as hazardous substance or mixture |
| Hazard Statements | Harmful if swallowed |
| First Aid (Eyes) | Flush with copious water for at least 15 minutes; seek medical attention |
| First Aid (Skin) | Wash thoroughly with water and soap |
| First Aid (Inhalation) | Move to fresh air; seek medical attention if symptoms persist |
| Personal Protective Equipment | Safety goggles, chemical-resistant gloves, laboratory coat |
| Engineering Controls | Adequate ventilation or local exhaust |
| Incompatible Materials | Strong oxidizing agents, strong bases |
6. Packaging & Logistics
| Aspect | Specification |
|---|---|
| Primary Container | Amber glass vial or validated polymer container, sealed under inert atmosphere |
| Secondary Packaging | Foil-laminate pouch with desiccant and oxygen absorber |
| Storage Condition Labeling | Clearly marked with recommended temperature range and RUO status |
| Transport Classification | Lyophilized peptide normally falls outside dangerous-goods classification |
| Logistics Considerations | Thermal lability and hygroscopicity are the primary commercial risks; validated temperature-controlled packaging with continuous monitoring is recommended |
7. Intended Use & Restrictions
Intended Users: Research institutions, laboratories, and qualified enterprises only. Not for sale to individual consumers.
Permitted Use: For research, laboratory, or further synthetic applications only.
Prohibited Use: Not for human injection, ingestion, diagnostic, or therapeutic use. Any pharmacological data referenced herein is provided solely for research context and does not constitute a warranty of safety or efficacy.
COA Verification Checklist:
-
CAS number and molecular form (free base vs. acetate)
-
Molecular weight matching the declared form
-
HPLC method and chromatographic conditions
-
Peptide content, water content, and counter-ion data
-
Route-derived impurity profile
-
Retest date supported by stability data
